Homepage > Rare diseases > Search

Search for a rare disease

*
(*) mandatory field

Hereditary butyrylcholinesterase deficiency

Suggest an update
Your message has been sent Your message has not been sent. Please contact an administrator.
Disease definition

Butyrylcholinesterase (BChE) deficiency is a metabolic disorder characterised by prolonged apnoea after the use of certain anaesthetic drugs, including the muscle relaxants succinylcholine or mivacurium and other ester local anaesthetics. The duration of the prolonged apnoea varies significantly depending on the extent of the enzyme deficiency.

ORPHA:132

Classification level: Disorder

Synonym(s):
  • Hereditary pseudocholinesterase deficiency

Prevalence: 1-9 / 100 000

Inheritance: Autosomal recessive

Age of onset: Infancy, Neonatal

ICD-10: E88.0

ICD-11: 5C59.Y

OMIM: 617936

UMLS: C1283400

MeSH: C537417

GARD: 7482

MedDRA: 10062674

Summary
Epidemiology

The prevalence of BChE deficiency is highest in the Caucasian population with between 3.4 and 4% of the population displaying a partial enzyme deficiency leading to slightly prolonged apnoea (between 5 minutes and 1 hour) and 1 in 2500 individuals showing a prolongation of more than 1 hour. Individuals with undetectable levels of BChE activity display a severe prolongation lasting more than 8 hours. The prevalence of this severe form is estimated at 1 in 100 000 individuals.

Etiology

BChE deficiency is a multifactorial disorder. It is caused by mutations in the BChE gene. The BChE gene is located at the E1 locus on chromosome 3 (3q26.1-q26.2) and multiple atypical variants have been identified. However, BChE deficiency and sensitivity to anaesthetic drugs may also occur during pregnancy, in neonates or in association with other pathologies (chronic infections, malnutrition, liver disease, certain cancers etc.).

Diagnostic methods

Diagnosis can be made by analysis of enzyme activity in plasma samples, combined with dibucaine and fluoride inhibition tests. DNA analysis, although not carried out routinely, can be used to identify heterozygous carriers of atypical alleles.

Genetic counseling

The hereditary condition is transmitted as an autosomal recessive trait.

Management and treatment

Affected individuals are asymptomatic unless exposed to neuromuscular blocking agents, however, prolonged respiratory paralysis following anaesthesia makes mechanical ventilation essential until the excess aesthetic agent is metabolised permitting normal neuromuscular function.

Last update: October 2006 - Expert reviewer(s): Pr Pascale DE LONLAY
A summary on this disease is available in Français (2006) Español (2006) Deutsch (2006) Italiano (2006) Nederlands (2006)
The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.